Simultaneous determination of 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl) uracil (FAU) and 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl) 5-methyluracil (FMAU) in human plasma by liquid chromatography/tandem mass spectrometry was written by Wiegand, Richard; Wu, Jianmei; Shields, Anthony F.; LoRusso, Patricia; Li, Jing. And the article was included in Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences in 2012.Computed Properties of C10H13FN2O5 The following contents are mentioned in the article:
A liquid chromatog. coupled with tandem mass spectrometry (LC-MS/MS) assay was developed and validated for simultaneous determination of 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl) uracil (FAU) and its active metabolite 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl) 5-methyluracil (FMAU) in human blood plasma. FAU and FMAU were extracted from plasma samples using solid-phase extraction with Waters Sep-Pak Vac C18 cartridge. Chromatog. separation was achieved on a Waters Atlantis T3 C18 column with a gradient mobile phase consisting of MeOH and water with 0.45% formic acid (volume/volume) running at a flow rate of 0.2 mL/min. The analytes were monitored by triple quadrupole mass spectrometer under pos. ionization mode. The lower limit of quantitation (LLOQ) was 10 and 2 ng/mL for FAU and FMAU in plasma, resp. Calibration curves were linear over FAU and FMAU plasma concentration range of 10-2000 and 2-1000 ng/mL, resp. The intra-day and inter-day accuracy and precision were within the generally accepted criteria for bioanal. method (<15%). The method was successfully employed to characterize the plasma pharmacokinetics of FAU and FMAU in cancer patients receiving 1-h i.v. infusion of FAU 50 mg/m2. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Computed Properties of C10H13FN2O5).
1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives. Drugs having the pyrimidine motif have manifested to exhibit gratifying biological activity like anticancer, antiviral, anti-inflammatory, antibacterial, and antihypertensive activities.Computed Properties of C10H13FN2O5
69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3